



Welcome to the July Q&A!

Trusts represented today include: North Bristol, Cambridge, Guy's and St Thomas', Exeter, Glasgow, Oxford, Norwich, Ayrshire, Cork, Salford, Leicester, RFH, St George's,

Q+A monthly meeting new format



- First presentation in June met with success... 😊
- 10-15 minute bite size presentation/update from an RPG member
 - Themes that regularly come up in the Whatsapp group (anticoagulation on HD)
 - Case presentations – opportunity for portfolio entry
 - Other updates from UKKA
- June Q+A
 - Robert Brown to present the UKKA presentation on Roxadustat
- July Q+A
 - Natasha Moore presenting the ERA/UKKW overview
- Aug Q+A
 - Louise Condon/Robert Brown presenting the two sides of the denosumab story
- Sept Q+A
 - ?BK talk from Leeds consultant

Any feedback/requests gratefully received 😊

New members to clinical sub-group welcome 😊




Updates

- **RPG conference 2024 11th/12th October** - Registration opens 28th June 😊
 - Birmingham Arden Hotel, £250 for full programme
 - Programme circulated via whatsapp
 - Abstract submissions open
- **UK Kidney week 11-13th June 2024**
 - Natasha Moore to provide a brief overview today
- Please complete RAG status survey for Clare Morlidge
 - Looking at national status for poster
 - Link in the whatsapp chat
 - [RAG Survey](#)
- Monthly teams chat for advanced/consultant portfolios
 - Email cathy.pogson@porthosp.nhs.uk if you would like to join
 - Members have been linked up into smaller groups to work together and then link back into the bigger group in time
 - Monthly meetings to suspend until over summer
- Reminder to check your RPG membership is up to date
 - Large number of lapsed memberships, currently being checked against the Q&A whatsapp group list
 - If you are not receiving the emails from UKKA, email the secretarial team (Caitlin Sewell)

Updates

- KRUK have opened applications for research grants 🎉
 - [Pharmacy-led research and research into nephrotoxicity grants](#)
 - Speak to Kathrine Parker, Dane Howard or Cathy Pogson for more information
- UKKA guidance on measles
- UKKA Education and Training Hub is now live
 - [UKKA Learning Hub \(ukkidney.org\)](#)
 - Resources on CKD, Glomerulonephritis and Transplantation
 - Other resources and links to follow



Our educational resources

eLearning Courses

Explore our advanced eLearning courses on diseases, comorbidities, treatments, workforce, and more. Designed by leading kidney care experts for healthcare professionals, these courses provide comprehensive insights into the latest advancements and best practices in kidney care, aiming to enhance patient experiences and outcomes.

Our Nephrology eLearning Courses

<p>CKD</p> <p>Cardiovascular, renal and metabolic diseases</p> <p>This course covers the relationship between renal function and CV disease, and the impact on patients with CKD. It describes the incidence and provides recommendations for the management of: Hypertension, Coronary artery disease, Arrhythmias/atrial fibrillation.</p> <p> Professor Debasish Banerjee</p> <p>Enrol</p>	<p>GN</p> <p>Glomerulonephritis</p> <p>This course covers the aetiology, pathology and clinical manifestations of the various types of glomerulonephritis (GN), pathophysiology, prognosis, and strategies.</p> <p> Professor Alan Salama</p> <p>Enrol</p>	<p>TX</p> <p>Management of Advanced Kidney Disease: Transplantation</p> <p>This course covers the principles, role, risks and benefits of renal transplantation in advanced kidney disease, including: donor-recipient matching, the impact of COVID-19, immunosuppression and risk.</p> <p> Professors Debasish Banerjee and Sandip Mitra</p> <p>0% COMPLETE</p> <p>Continue</p>
--	---	--



Conference Report

ERA & UKKW

NATASHA MOORE – GUY'S AND ST THOMAS'

ERA 2024

Stockholm

Late Breaking clinical Trials



- The FLOW study:
 - Semaglutide in T2DM
 - eGFR 25-75 on RAASi 12% of patients eGFR<30
 - Double blind, randomised, placebo controlled, worldwide
 - Primary outcome was major kidney disease events
 - these were 24% lower in treatment arm
 - Reduction in eGFR slope of 1.16ml/yr
 - HR 0.79 for renal outcome, HR 0.71 for all cardiovascular causes
 - Also REWIND = dulaglutide = reduction of 25% of renal outcomes
- ALIGN – early results Phase 3 trial
 - Atrasentan in IgAN – endothelin A receptor antagonist in addition to ACEi/ARB
 - Reduction in proteinuria of 36% vs placebo


ERA 2024

Key messages coming out

- IgAN – lots of new therapies being trialled
 - Turn off IgA production (budesonide) AND reduce glomerular inflammation (BAFF / APRIL or complement) AND treat CKD – ACEi/ARB endothelin antagonists
 - Complement – iptacopan / ravalizumab
 - BAFF / APRIL – sibeprenlimab / atacicept / zigakibert

- NHSE doing some work on how these will be funded / fit into a pathway.....

- Treatment for CKD with T2DM – 4 pillars
 - ACEi/ARB
 - SGLT2i
 - MRA
 - GLP-1



UKKW 2024

- IgAN
 - Again the new medications that are being trialled
 - Message around stopping the disease progression and treating the CKD progression
 - Changing the mind set to more like AAV – stop disease progression
- Lupus
 - Use of voclosporin – high cost CNI – licensed and being used in some centres – discussion around whether tacrolimus is as good – but not proven in trial or licensed.
- RPG talks
 - Robert – Roxadustat use across the UK – already presented at a Q&A
 - Denise – uromune clinic and use of a vaccine

UKKW 2024

- CKD
 - Kidney networks at different places with CKD optimisation
 - Lots of data sources out there but no one good source
 - LUCID project Leicestershire
 - 1) education (using the Leicester videos for patients too)
 - 2) identification of patients (for LUCID clinics)
 - 3) Optimising (medicines)
 - 4) Surveillance (monitoring for progression of CKD)
 - With right person, Rupert emphasised a pharmacist colleague, from the PCN can now run LUCID clinic independently.
 - Funding – going forwards
- Morgan Grams (New York/ KDIGO) keynote speaker
 - emphasised need to optimise CKD management
 - KFRE does not correct for risk of death
 - People at greatest risk of death have greatest benefit from therapy

RPG successes

Posters / presentations

Posters

- Aisha from Guys won her poster on 'pharmacist in a pre-op transplant clinic'
- Wales – use of SGLT2i in transplant patients
- Dane, Janette Chu and Chris Herrings poster 'Mycophenolate contraception advice; a review of practice across renal transplant units throughout the United Kingdom (UK)' won best poster in their group
- Olivia, Issac and Natasha had a poster titled 'A multicentre service evaluation of the role and impact of renal pharmacist participation in haemodialysis patient multidisciplinary team reviews'
- Kathrine two posters 'Supporting shared-decision making for anticoagulants in people with advanced kidney disease' and 'Best practice for the selection, design and implementation of UK Kidney Association guidelines: a Delphi consensus approach'.

Q&A – UKRPG Conference 11th/12th October 2024



- **40th Anniversary of RPG Conference!**
- Conference registration opens 21st June
- £250 for both days (including dinner/celebrations and accommodation on Friday evening)
- Abstract submission opens 28th June
- All posters/abstracts encouraged including if presented at UKKW
- Looking for more volunteers to join the conference committee
- Looking for abstract markers and facilitators for the conference
- Contact linda.ross@gstt.nhs.uk / poojamehta.gudka@nhs.net to get involved
- A number of bursaries may be available – further details to follow, however please do start exploring local funding options ASAP

Supply Problems



- Sando K/slow Na/sando phos
 - Supplies appear resolved
- Taurolock U/Alteplase
 - Taurolock U back?
 - Alteplase 2mg still OOS – options include ULM alteplase (cost pressure) or urokinase
- Mycophenolic acid 360mg
 - Generic issues ongoing, Sandoz are limiting supplies to instalments for homecare companies
- Ibandronate/Pamidronate
 - Unlicensed pamidronate being explored
 - Some centres looking into using zolendronic acid/denosumab depending in indication

Supply Problems



- Ganciclovir
 - Vials in stock, some supplies of pre made bags
- 5% HAS
 - Units diluting higher strength HAS to achieve 5% concentration
- Finerenone – not a supply issue but single wholesaler route presenting problems
- Budesonide – not supply issue but issues getting accounts set up, now available through Phoenix.
 - ? How to manage acute illness - ?need to double dose - TBC
- Basiliximab – transplant centres on monthly allocation, unlicensed supplies available but very £££
 - ? National UK stock coming in earlier. Problems with unlicensed stock coming in – import ban with restricted stock. Units should escalate to national commissioners about cost pressures. Trusts being asked to utilise mutual aid

Q&A Themes - Guidelines



- Monthly evidence update from Portsmouth clinical librarians 🙌
- Avacopan guideline
- ATG for transplant induction
- Workforce planning documents – currently BRS document from 2020 most up to date.
UKKA summit looking at workforce in the autumn
- Renal pharmacist band 7 to band 8 terms of framework
- Sodium bicarbonate 1.4 %
- Primary care talks on CKD management
- Osteoporosis guidelines in CKD

Q&A Themes - Renal



- Avacopan eligible patients
- Inadine (PVP-I) non-adherent dressings – CI in kidney disease
- Roxadustat for very low body weight (max tolerated dose 3 mg/kg body weight)
- UKKA enquiry – which trusts permit pharmacy technicians to liaise with clinicians regarding withholding/restarting medications of nephrotoxic potential
- Rituximab for glomerular diseases
- **Tetrabenazine in eGFR 13 ml/min**
- Prescribing restrictions in SGLT2 inhibitors – warnings for DKA
- DDAVP for high risk biopsies
- Membranous/MCD – regular Rituximab based on CD19 counts or wait for relapse
- Tolvaptan – NICE criteria or ERA recommended age-index GFR model to identify rapidly progressing disease



Q&A Themes - Dialysis

- Hydroxycobalamin IV on dialysis
- **Riluzole on dialysis**
- Dispensing of etelcalcetide for dialysis units
- Cabotegravir-Rilpivirine injections on HD
- Sodium cromoglicate in ESRD
- Amikacin doses on HD
- GLP1 agonists in HD patients to achieve weight reduction to get them on the list for transplant
- **Rotigotine patches for restless legs in HD**
- Hyperkalaemia with oral labetalol



Q&A Themes - Transplant

- IP course in transplant
- Mannose prophylaxis against UTIs in transplant
- SGLT2 inhibitors in transplant patients
- Efudix 5 % cream in renal transplant patients
- Dose adjustment between Adoport and tacrolimus liquid
- Immunosuppression with kennel cough vaccine
- HRT in CKD/transplantation
- CMV – how long for prophylaxis following two negative results

June Q&A - Close



Thank you for attending!

Next Q&A: Tuesday 20th August

Keep in touch throughout the month on **WhatsApp Q&A Group**

- >100 participants throughout UK and Ireland
- Useful real time forum for clinical Q's
- Please consider joining!

